First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...

(RTTNews) - UNITY Biotechnology, Inc. (UBX) Wednesday reported results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not ...

Sana Biotechnology, Inc. ((SANA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Vir Biotechnology, Inc. VIR announced new encouraging preliminary data from its phase II SOLSTICE study. Its shares rose 19.7% on the news. The study is evaluating the safety, tolerability and ...

On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

A study released in December of 2024 has found that drones not only can provide rural residents with access to healthcare resources, but that rural people are eager to embrace the new technology.

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...